Abstract:In non-small cell lung cancer (NSCLC), the composition and structure of the tumor immune microenvironment (TME) critically impact patient outcomes, necessitating improved computational approaches to characterize the TME beyond traditional metrics like the PD-L1 tumor proportion score (TPS). Here, we developed an interpretable deep-learning model that robustly predicts patient overall survival (OS) and identifies unique PD-L1 enriched neighborhoods linked to patient prognosis. We utilized a dataset of 507 NSCLC patient biopsy samples prospectively acquired as part of the DFCI ImmunoPROFILE project. Each sample was stained for Cytokeratin as tumor marker, PD-L1, PD-1, CD8, and FOXP3 using a targeted multiplex immunofluorescence assay. Inner tumor regions of interest were automatically processed for spatially resolved identification and quantification of marker expression at the single-cell level. The dataset was divided into 380 patients for model development and 127 for testing. The deep-learning model, a graph neural network (GNN), was trained to predict OS based on local cell neighborhoods using a weakly supervised training paradigm. The GNN models neighborhoods as a graph, with cells and their corresponding marker expression representing nodes and edges connecting adjacent cells, for an average of 42 cells per neighborhood. Survival predictions were obtained by averaging predictions over all neighborhoods from one sample. The GNN model demonstrated robust performance with a concordance index (c-index) of 0.79 on the test data, surpassing traditional metrics such as TPS and immune marker density-based models (c-index: 0.50 and 0.74, respectively). Beyond assessing performance, we investigated the features learned by the GNN using k-means clustering in the model's feature space. We identified three clusters that were notably enriched in PD-L1 positive tumor cells. The first cluster shows an especially "high TPS" phenotype, where the GNN predicted such neighborhoods to be generally poor for survival. The other two clusters were additionally enriched with PD-L1 positive immune cells (ICs) and associated with favorable survival predictions. Notably, one cluster was also enriched with other types of ICs ("PD-L1 IC mixed"), which the GNN predicted as especially favorable for survival compared to exclusive enrichment of PD-L1 ICs ("PD-L1 IC dominant"). A score summarizing these three PD-L1 expression patterns was significantly associated with OS (p-value: 0.01; HR: 0.72, 95% CI: 0.16-1.27), validating the features learned by the GNN. In sum, we developed a highly interpretable deep-learning model leveraging cellular neighborhood graphs, which effectively identifies expression patterns correlating with NSCLC prognosis, offering promise for developing personalized treatment strategies. Citation Format: Katharina Viktoria Hoebel, James R. Lindsay, Joao V. Alessi, Jason L. Weirather, Ian D. Dryg, Jennifer Altreuter, Mark M. Awad, Scott J. Rodig, William E. Lotter. Deep-learning model trained on multiplex immunofluorescence-stained tissue samples predicts the survival of patients with non-small cell lung cancer better than PD-L1 TPS alone [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6189.

A multi-omics-based serial deep learning approach to predict clinical outcomes of single-agent anti-PD-1/PD-L1 immunotherapy in advanced stage non-small-cell lung cancer

Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients.

Multimodal machine learning model prediction of “individual” response to immunotherapy in 1L stage IV NSCLC.

Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1/PD-L1 blockade

Real-world and clinical trial validation of a deep learning radiomic biomarker for PD-(L)1 immune checkpoint inhibitor response in stage IV NSCLC.

Deep learning for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall survival risk

Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study

Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer

Clinical multi-dimensional prognostic nomogram for predicting the efficacy of immunotherapy in NSCLC

Non-Invasive Measurement Using Deep Learning Algorithm Based on Multi-Source Features Fusion to Predict PD-L1 Expression and Survival in NSCLC

A Combined-Radiomics Approach of CT Images to Predict Response to Anti-PD-1 Immunotherapy in NSCLC: A Retrospective Multicenter Study

Assessing the robustness of radiomics/deep learning approach in the identification of efficacy of anti-PD-1 treatment in advanced or metastatic non-small cell lung carcinoma patients

Predicting the efficacy of immune checkpoint inhibitors monotherapy in advanced non-small cell lung cancer: a machine learning method based on multidimensional data

Abstract 6189: Deep-learning model trained on multiplex immunofluorescence-stained tissue samples predicts the survival of patients with non-small cell lung cancer better than PD-L1 TPS alone

Abstract 6401: Predictive models for first-line immunotherapy based on spatial tumor immune microenvironment in patients with advanced non-small cell lung cancer (NSCLC)

Improving Prediction of Survival and Progression in Metastatic Non-Small Cell Lung Cancer Following Immunotherapy Through Machine Learning of Circulating Tumor DNA Dynamics

Improving Prediction of Survival and Progression in Metastatic Non-Small Cell Lung Cancer After Immunotherapy Through Machine Learning of Circulating Tumor DNA

Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images

A Machine Learning Algorithm for Predicting Therapeutic Response to Anti-PD1

Longitudinal High-Dimensional Analysis Identifies Biomarkers of Response to Anti-PD-1 Immunotherapy

Clinical Significance and Molecular Annotation for PD-L1 Negative Advanced Non-Small Cell Lung Cancer with Sensitivity to Responsive to Dual PD-1/CTLA-4 Blockade